Literature DB >> 33312062

Assessment of serum tenascin-C and growth differentiation factor-15 among type 2 diabetes mellitus patients with and without acute coronary syndrome.

Murugaiyan Vasanthi1, Prashant Shankarrao Adole1, Vinay Ramakrishna Pandit2, Kolar Vishwanath Vinod3.   

Abstract

BACKGROUND: High prevalence of type 2 diabetes mellitus (T2DM) is associated with a higher prevalence of acute coronary syndrome (ACS). Inflammation is one of the important contributors to the pathogenesis and complications of coronary atherosclerotic plaque. Growth Differentiation Factor-15 (GDF-15) and Tenascin-C (TNC) play an important role in the initiation of atherosclerotic plaque as well as its rupture. The aim of the study was to evaluate the association between serum GDF-15, TNC, and the risk of ACS among T2DM patients.
METHODS: Anthropometric parameters, routine biochemical investigations like liver and renal function tests, lipid profile, and Creatine Kinase-Total (CK-T), Creatine Kinase-MB (CK-MB) were measured in 42 T2DM patients with ACS and 42 T2DM patients. Serum GDF-15 and TNC were measured by Human Sandwich-ELISA kits.
RESULTS: Serum GDF-15 and TNC levels were significantly higher in T2DM patients with ACS as compared to T2DM patients. Serum GDF-15 was significantly correlated with waist circumference, diastolic blood pressure, pulse, serum CK-T, and CK-MB. Serum TNC was significantly correlated with the pulse, serum CK-T, CK-MB, high-density lipoprotein-cholesterol, and blood urea nitro GEN. Multivariate linear regression analysis showed that waist circumference was independently positively associated with serum GDF-15.
CONCLUSIONS: T2DM patients with higher serum GDF-15 and TNC levels were at higher risk of acute coronary syndrome independent of other cardiovascular risk factors. 2020 Murugaiyan Vasanthi, Prashant Shankarrao Adole, Vinay Ramakrishna Pandit, Kolar Vishwanath Vinod, published by CEON/CEES.

Entities:  

Keywords:  acute coronary syndrome; growth differentiation factor-15; tenascin-C; type 2 diabetes mellitus

Year:  2020        PMID: 33312062      PMCID: PMC7710370          DOI: 10.5937/jomb0-24662

Source DB:  PubMed          Journal:  J Med Biochem        ISSN: 1452-8266            Impact factor:   3.402


  19 in total

1.  High tenascin-C levels cause inadequate myocardial blush grade in patients with acute myocardial infarction.

Authors:  Ozlem Arican Ozluk; Dursun Topal; Erhan Tenekecioglu; Tezcan Peker; Mustafa Yilmaz; Kemal Karaagac; Fahriye Vatansever; Bedrettin Boyraz; Omur Aydın
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study.

Authors:  Lars Lind; Lars Wallentin; Tibor Kempf; Heike Tapken; Anja Quint; Bertil Lindahl; Sylvia Olofsson; Per Venge; Anders Larsson; Johannes Hulthe; Anders Elmgren; Kai C Wollert
Journal:  Eur Heart J       Date:  2009-06-26       Impact factor: 29.983

Review 3.  Tenascin-C in cardiovascular remodeling: potential impact for diagnosis, prognosis estimation and targeted therapy.

Authors:  Marcus Franz; Christian Jung; Alexander Lauten; Hans R Figulla; Alexander Berndt
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

4.  [Value of plasma growth differentiation factor-15 in diagnosis and evaluation of type 2 diabetic nephropathy].

Authors:  Hui Li; Fang Gao; Yaoming Xue; Yi Qian
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2014-03

Review 5.  Diabetes mellitus and acute coronary syndrome: lessons from randomized clinical trials.

Authors:  Sanjum S Sethi; Elias G Akl; Michael E Farkouh
Journal:  Curr Diab Rep       Date:  2012-06       Impact factor: 4.810

6.  Growth differentiation factor 15 and cardiovascular events in patients with stable ischemic heart disease (The Heart and Soul Study).

Authors:  David W Schopfer; Ivy A Ku; Mathilda Regan; Mary A Whooley
Journal:  Am Heart J       Date:  2013-10-17       Impact factor: 4.749

7.  Serum tenascin-C level is associated with coronary plaque rupture in patients with acute coronary syndrome.

Authors:  Nobuo Sakamoto; Yasuto Hoshino; Tomofumi Misaka; Hiroyuki Mizukami; Satoshi Suzuki; Koichi Sugimoto; Takayoshi Yamaki; Hiroyuki Kunii; Kazuhiko Nakazato; Hitoshi Suzuki; Shu-ichi Saitoh; Yasuchika Takeishi
Journal:  Heart Vessels       Date:  2013-03-27       Impact factor: 2.037

8.  Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in obese nondiabetic individuals: results from the XENDOS trial.

Authors:  Tibor Kempf; Anja Guba-Quint; Jarl Torgerson; Maria Chiara Magnone; Carolina Haefliger; Maria Bobadilla; Kai C Wollert
Journal:  Eur J Endocrinol       Date:  2012-08-23       Impact factor: 6.664

9.  Tenascin-C is associated with coronary plaque instability in patients with acute coronary syndromes.

Authors:  Kajiwara Kenji; Ueda Hironori; Yamamoto Hideya; Imazu Michinori; Hayashi Yasuhiko; Kohno Nobuoki
Journal:  Circ J       Date:  2004-03       Impact factor: 2.993

10.  Clinical implications of tenascin-C and OX40 ligand in patients with acute coronary syndrome.

Authors:  Jin-Hu Yang; Feng Ren
Journal:  Biomed Rep       Date:  2013-11-04
View more
  2 in total

1.  Associations Between Tenascin-C and Testosterone Deficiency in Men with Major Depressive Disorder: A Cross-Sectional Retrospective Study.

Authors:  Rui Peng; Yan Li
Journal:  J Inflamm Res       Date:  2021-03-16

2.  Is serum fibroblast growth factor 21 associated with the severity or presence of coronary artery disease?

Authors:  Gokay Nar; Sanlialp Sara Cetin; Rukiye Nar; Oguz Kilic; Ozen Mehmet Furkan; Guven Gunver; Sevgican Cihan Ilyas
Journal:  J Med Biochem       Date:  2022-04-08       Impact factor: 2.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.